Medicines Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/10/2019)
| Balance Sheet | Total Assets | 841,686,000.00 | ROE | – |
| Balance Sheet | Total Equity | -22,000,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -7,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -261,802,000.00 | – | – |
| Cashflow | Operating Cash Flow | -261,795,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -1.68 | Div. Yield | – |
| Income | Net Income | -123,156,000.00 | P/E | – |
| Income | Shares Outstanding | 73,307,100.00 | P/B | – |
| Income | Total Revenue | 6,138,000.00 | P/S | – |
Ratios calculated on: –
Company Description
The Medicines Company, is a pharmaceutical company focused on the treatment of critical care patients through the delivery of medicines to the global hospital marketplace. The Company has three marketed products: Angiomax(bivalirudin), Cleviprex (clevidipine butyrate) injectable emulsion and its ready-to-use formulation of Argatroban. It also has a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. All of its acute care generic products are injectable products. In January 2013, the Company acquired Incline Therapeutics Inc. Effective August 5, 2013, The Medicines Company acquired the entire interest of ProFibrix BV, a biotechnology company. Effective December 4, 2013, The Medicines Co acquired Rempex Pharmaceuticals Inc.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.themedicinescompany.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more